A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
About this study
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
- Condition
- The First Affiliated Hospital of Nanchang University
- Tested
- Orelabrutinib+R-CHOP
- Sponsor
- Shandong Cancer Hospital and Institute
Who can join
- Age
- 18 to 70 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Maximum age: 70 years
- Study condition: The First Affiliated Hospital of Nanchang University
- Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
- Age 18-70 years
- ECOG performance status 0-2
- Ann Arbor stage II-IV
- 8.Subjects who in line with the testing standard of the clinical trial laboratory
- Life expectancy ≥ 3months
Exclusion 5
- • systemic lymphoma involved CNS.
- Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases.
- uncontrolled infections (including HBV, HCV, HIV/AIDS)
- Subjects who prepared for transplantation
- Pregnancy or active lactation
Where
2 sites, 2 recruiting
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Jinan, Shandong, China
The First Ailliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact
-
zengjun Li
13642138692 zengjunli@163.com
-
Dan Liu
13256139207
Potential match only. Final eligibility is determined by the study team.